ATE263247T1 - Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate - Google Patents

Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate

Info

Publication number
ATE263247T1
ATE263247T1 AT98100603T AT98100603T ATE263247T1 AT E263247 T1 ATE263247 T1 AT E263247T1 AT 98100603 T AT98100603 T AT 98100603T AT 98100603 T AT98100603 T AT 98100603T AT E263247 T1 ATE263247 T1 AT E263247T1
Authority
AT
Austria
Prior art keywords
pep
joined
peptide
fusion protein
image
Prior art date
Application number
AT98100603T
Other languages
English (en)
Inventor
Alan L Epstein
Leslie A Khawli
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE263247T1 publication Critical patent/ATE263247T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98100603T 1998-01-09 1998-01-15 Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate ATE263247T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2219961A CA2219961C (en) 1998-01-09 1998-01-09 Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
AU51821/98A AU5182198A (en) 1998-01-09 1998-01-12 Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
EP98100603A EP0931836B1 (de) 1998-01-09 1998-01-15 Peptid aus humanem Interleukin-2 zur Steigerung der Vasopermeabilität und dessen Immunkonjugate

Publications (1)

Publication Number Publication Date
ATE263247T1 true ATE263247T1 (de) 2004-04-15

Family

ID=31720801

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98100603T ATE263247T1 (de) 1998-01-09 1998-01-15 Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate

Country Status (7)

Country Link
EP (1) EP0931836B1 (de)
AT (1) ATE263247T1 (de)
AU (1) AU5182198A (de)
CA (1) CA2219961C (de)
DE (1) DE69822779T2 (de)
ES (1) ES2218717T3 (de)
HK (1) HK1023788A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US20200223894A1 (en) * 2017-09-19 2020-07-16 Auckland Uniservices Limited Peptides for the treatment of conditions associated with adiponectin dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
IL91933A (en) * 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
JPH0720991B2 (ja) * 1989-02-08 1995-03-08 株式会社クラレ 新規なペプチドおよびその用途

Also Published As

Publication number Publication date
ES2218717T3 (es) 2004-11-16
DE69822779D1 (de) 2004-05-06
EP0931836A1 (de) 1999-07-28
CA2219961A1 (en) 1999-07-09
AU5182198A (en) 1999-07-29
CA2219961C (en) 2010-06-01
EP0931836B1 (de) 2004-03-31
DE69822779T2 (de) 2005-03-10
HK1023788A1 (en) 2000-09-22

Similar Documents

Publication Publication Date Title
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
DE69807679T2 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
MA27544A1 (fr) Conjugues de l'hormone de croissance humaine chimiquement modifies.
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
ATE373712T1 (de) Natürlicher menschlicher antikörper
FI911319A0 (fi) Polypeptidderivat.
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
DK1642972T3 (da) Terapeutisk anvendelse af BR43X2 opløselige receptorer
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
MXPA05007843A (es) Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
ES2134212T3 (es) Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
IL171779A (en) Immunoconjugates comprising an immunoglobulin constant region and a biologically active molecule
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
RU2017101662A (ru) Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения
DE60136054D1 (de) Apoptose-induzierendes polypeptid
TR200001961T2 (tr) Ifnar 2/IFN kompleksi.
ATE263247T1 (de) Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate
NO20033718D0 (no) Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus
MX2023005571A (es) Metodos de tratamiento de canceres que expresan axl con anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados.
RU2023123071A (ru) Способы предотвращения окисления метионина в иммуноконъюгатах
UA88604C2 (ru) Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания
RU2350351C2 (ru) Композиции и лекарственные формы на основе гастрина, методы применения и получения
ES2114527T3 (es) Anticuerpos que reconocen especificamente la proteina de enlace de la somatotropina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0931836

Country of ref document: EP

REN Ceased due to non-payment of the annual fee